Cipla investing heavily in digitisation and emerging markets
Cipla is betting big on digitisation and emerging segments like biosimilars and mRNA-assisted medications to drive its next phase of growth and also optimistic about capitalizing on value opportunities in the complex generics market in the United States.
IPC issues safety alert for immunosuppressive drug tacrolimus
Indian Pharmacopoeia Commission (IPC), which serves as the National Coordination Centre (NCC) for the Pharmacovigilance Programme of India has issued a drug safety alert revealing that the immunosuppressive medication tacrolimus is linked to gingival hypertrophy.
Gifts and Freebies for Prescriptions: Pharma Bribery of Doctors topic in Parliament
The issue of pharmaceutical companies engaging in unfair and unethical practices to promote their medicines by sponsoring trips and providing gifts to doctors recently came up in Lok Sabha sessions.
Lumakras plus immunotherapy for lung cancer needs more research, as per Amgen
According to the company, a small study of Amgen Inc’s Lumakras drug combined with immunotherapy found it helped 29 percent of advanced lung cancer patients, but liver toxicity was high and more research is needed.
Pharma companies enlisted by Govtto encourage employee participation in "Har Ghar Tiranga"
To promote the ‘Har Ghar Tiranga’ programme, the Department of Pharmaceuticals has written to the Indian Drug Manufacturers Association and other stakeholders.
AiMeD requests creation of separate Dept for medical devices from Prime Minister
Association of Indian Medical Device Industry (AiMeD) has urged Prime Minister Narendra Modi to either rename the Department of Pharmaceuticals to the Department of Pharmaceuticals & Medical Devices or create a separate Department of Medical Devices.
US FDA approved AstraZeneca's new Calquence tablet formulation for all current indications
All current indications for Calquence, including
adult patients with chronic lymphocytic
leukemia, small lymphocytic lymphoma, and
patients with relapsed or refractory mantle cell
lymphoma, have been given accelerated
approval in the US by AstraZeneca based on
overall response rate.
